{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:22:03Z","timestamp":1773865323982,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1016\/j.leukres.2007.05.003","type":"journal-article","created":{"date-parts":[[2007,7,21]],"date-time":"2007-07-21T11:23:41Z","timestamp":1185017021000},"page":"71-77","source":"Crossref","is-referenced-by-count":92,"title":["A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine\u00ae) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders"],"prefix":"10.1016","volume":"32","author":[{"given":"Judith E.","family":"Karp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis J.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Gojo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Greer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonny","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mya","family":"Thein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Sznol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Low","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2007.05.003_bib1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0079-6107(01)00014-1","article-title":"Structure and function of the radical enzyme ribonucleotide reductase","volume":"77","author":"Eklund","year":"2001","journal-title":"Prog Biophys Mol Biol"},{"key":"10.1016\/j.leukres.2007.05.003_bib2","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1139\/o90-199","article-title":"Regulation and drug resistance mechanisms of mammalian ribonucleotide reductase, and the significant to DNA synthesis","volume":"68","author":"Wright","year":"1990","journal-title":"Biochem Cell Biol"},{"key":"10.1016\/j.leukres.2007.05.003_bib3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0006-2952(94)90105-8","article-title":"Inhibitors of ribonucleotide reductase. Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones","volume":"48","author":"Cory","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.leukres.2007.05.003_bib4","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1021\/jm9600454","article-title":"Synthesis and biologic activity of 3- and 5-amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone","volume":"39","author":"Liu","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/j.leukres.2007.05.003_bib5","first-page":"235","article-title":"Inhibition of deoxyribonculeotide synthesis by pyridine carboxaldehyde thiosemicarbazones","volume":"31","author":"Moore","year":"1971","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2007.05.003_bib6","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2007.05.003_bib7","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1182\/blood.V82.2.398.398","article-title":"Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea","volume":"82","author":"Hehlmann","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2007.05.003_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.V46.1.11.11","article-title":"Hydroxyurea in the management of the hematologic complications of chronic granulocytic leukemia","volume":"46","author":"Schwartz","year":"1975","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2007.05.003_bib9","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1182\/blood-2001-12-0349","article-title":"Polycythemia vera: myths, mechanisms, and management","volume":"100","author":"Spivak","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2007.05.003_bib10","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1182\/blood.V88.7.2480.bloodjournal8872480","article-title":"A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia","volume":"88","author":"Wattel","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2007.05.003_bib11","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0006-2952(99)00419-0","article-title":"Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity","volume":"59","author":"Finch","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.leukres.2007.05.003_bib12","doi-asserted-by":"crossref","first-page":"26200","DOI":"10.1016\/S0021-9258(19)74300-2","article-title":"Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators","volume":"268","author":"Nyholm","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2007.05.003_bib13","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0145-2126(03)00118-8","article-title":"Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia","volume":"27","author":"Giles","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2007.05.003_bib14","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.leukres.2007.01.004","article-title":"Phase I and pharmacokinetic study of Triapine\u00ae, a potent ribonucleotide reductase inhibitor, I adults with advanced hematologic malignancies","volume":"31","author":"Gojo","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2007.05.003_bib15","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1182\/blood.V78.11.2937.2937","article-title":"Effects of thymidine and hydroxyurea on the metabolism and cytotoxicity of 1-B-D-arabinofuranosylcytosine in highly resistant human leukemic cells","volume":"78","author":"Bhalla","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2007.05.003_bib16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/BF01715122","article-title":"Increase in Ara-C sensitivity in Ara-C sensitive and -resistant leukemia by stimulation of the salvage and inhibition of the de novo pathway","volume":"65","author":"Colly","year":"1992","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2007.05.003_bib17","first-page":"329","article-title":"Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemic cells","volume":"48","author":"Gandhi","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2007.05.003_bib18","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/blood.V90.1.270","article-title":"Differential incorporation of Ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating leukemia cells","volume":"90","author":"Iwasaki","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2007.05.003_bib19","first-page":"2688","article-title":"Biochemical and cytokinetic modulation of L1210 and HL-60 cells by hydroxyurea and effect of 1-b-d-arabinofuranosylcytosine metabolism and cytotoxicity","volume":"43","author":"Rauscher","year":"1983","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2007.05.003_bib20","first-page":"7290735","article-title":"Mechanism of synergistic cell killing by hydroxyurea and cytosine arabinoside","volume":"76","author":"Tanaka","year":"1985","journal-title":"Jpn J Cancer Res"},{"key":"10.1016\/j.leukres.2007.05.003_bib21","first-page":"3286","article-title":"Increased activation of 1-beta-D-arabinofuranosylcytosine by hydroxyurea in L1210 cells","volume":"40","author":"Walsh","year":"1980","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2007.05.003_bib22","first-page":"1369","article-title":"Time and sequence dependence of hydroxyurea in combination with gemcitabine in human KB cells","volume":"22","author":"Zhou","year":"2002","journal-title":"Anticancer Res"},{"key":"10.1016\/j.leukres.2007.05.003_bib23","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1200\/JCO.1998.16.7.2321","article-title":"Cellular pharmacodynamics of parenterally infused hydroxyurea during a phase I clinical tiral in chronic myelogenous leukemia","volume":"16","author":"Gandhi","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2007.05.003_bib24","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.leukres.2005.12.013","article-title":"Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome","volume":"30","author":"Yee","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2007.05.003_bib25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1200\/JCO.1991.9.1.175","article-title":"Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies","volume":"9","author":"Chun","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2007.05.003_bib26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF00685844","article-title":"Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event","volume":"3","author":"Huang","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.leukres.2007.05.003_bib27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.1993.11.1.116","article-title":"Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy","volume":"11","author":"Gandhi","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2007.05.003_bib28","first-page":"1225","article-title":"Central nervous system toxicity of fludarabine phosphate","volume":"70","author":"Chun","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.leukres.2007.05.003_bib29","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.1986.4.1.74","article-title":"Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity","volume":"4","author":"Warrell","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2007.05.003_bib30","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1038\/sj.leu.2401684","article-title":"In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis","volume":"14","author":"Kano","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2007.05.003_bib31","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.1994.12.4.671","volume":"12","author":"Estey","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2007.05.003_bib32","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1997.15.8.2780","article-title":"Phase I\/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Clindren's Cancer Group","volume":"15","author":"Dinndorf","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2007.05.003_bib33","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1046\/j.1365-2141.1998.00836.x","article-title":"IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial","volume":"102","author":"Fleischhack","year":"1998","journal-title":"Britisih J Haem"},{"key":"10.1016\/j.leukres.2007.05.003_bib34","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2007.05.003_bib35","first-page":"3671","article-title":"Report of an international working group to standardize response criteria for myelodysplastic syndromes","volume":"96","author":"Cheson","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2007.05.003_bib36","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/cncr.11315","article-title":"Phase II study of SU5416, a small molecule vascular endothelial growth factor (VEGF) tyrosine kinase receptor inhibitor, in patients with refractory myeloproliferative diseases","volume":"97","author":"Giles","year":"2003","journal-title":"Cancer"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212607001890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212607001890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T06:42:27Z","timestamp":1629441747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212607001890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S0145212607001890"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2007.05.003","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}